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Stabilisation of an amorphous form of ROY
through a predicted co-former interaction†
Philip A. Corner,a J. Jonathan Harburn,a Jonathan W. Steed,b James F. McCabec
and David J. Berry*a
The highly polymorphic compound ROY, notorious for the colour of
its crystals, was the subject of an optimised high-throughput
ultrasound-based co-crystal screen. This screen involved a computa-
tional pre-screen which highlighted an interaction between ROY and
the potential co-former pyrogallol. We have shown that the presence
of pyrogallol stabilises the amorphous form of ROY, highlighting the
potential for future prediction of co-amorphous behaviours.
The olanzapine precursor ROY (Fig. 1), 5-methyl-2-[(2-nitro-
phenyl)amino]-3-thiophenecarbonitrile, so called due to the red,
orange and yellow crystal colours of its polymorphs, has been
reported to exist in at least 10 polymorphic forms.1 With seven of
these forms structurally characterised, it was until recently2 the
compound with the most polymorphs recorded in the Cambridge
Structural Database (CSD).3 Due to the large number of polymorphic
forms of ROY, it was chosen as a model compound for co-crystal
screening. In this work ROY was first synthesised following the
procedure reported in the patent for the synthesis of Olanzapine.4
Analysis of the resulting material is present in the ESI† (S1–S4).
It is the practice of the pharmaceutical industry to perform
comprehensive polymorph screening during the development of a
drug.5 Although a metastable crystalline polymorphic form may
give benefits in terms of solubility, the risk of conversion to the less
bioavailable form at ambient conditions means this option is
seldom used. Solubility advantage can also be conferred by the
amorphous form.6–9 These phases however also have the potential
to convert to a thermodynamically more stable crystalline form.
The timescale of this conversion dictates the degree of opportunity
or risk associated with the phase.10 Stabilisation techniques such
as formulating the product with the addition of a polymer have
been widely studied11–13 and can yield suitable stability at a cost –
financial in terms of greater development needed for the formula-
tion, additional regulatory requirements and issues surrounding
the quantity of active pharmaceutical ingredient (API) that is
contained within a formulation (i.e. drug loading).14
Many of the polymers used in stabilising drugs in this way
(such as PVP, PVPVA and HPMC6) are hygroscopic15 and can lead
to faster re-crystallisation of the drug through modification of the
glass transition (Tg), removing the solubility benefit. There are also
issues associated with HPMC which can cause a laxative effect.16
These deficiencies have led to an expansion in research in
co-amorphous materials.17,18 Co-amorphous phases have been
the subject of significant study since 2009 as they have the
potential to solve the problems of drug loading and toxicity.
The co-amorphous approach has been defined as ‘the combi-
nation of two or more low molecular weight components that
form a homogeneous amorphous single-phase system’.19 The
stabilising interactions have been seen to occur via a number of
mechanisms including hydrogen bonding, p–p stacking and salt
formation. There are currently no purported means of predicting
which small molecules will create such interactions and stabilise
APIs in the desired fashion. This means many thousands of
potential molecules could be used as the second entity, therefore
some mechanism for practical selection would be beneficial.
Co-crystal formation can also convey advantageous properties to
pharmaceuticals.20,21 Without extensive screening it is not currently
possible to know with certainty which co-formers, if any, will form a
co-crystal with a given API. Crystal structure prediction (CSP) is a
developing field with the potential to correctly predict structure
Fig. 1 Structures of ROY, pyrogallol and PVP.
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improving year on year, as evidenced by the blind tests organised by
the Cambridge Crystallographic Data Centre (CCDC).22 There is still
much work to be done regarding prediction of the result of
introducing a co-former into the crystal structure, in terms of
physical and chemical properties. It is therefore necessary to per-
form empirical screening and analysis to obtain co-crystals for a
given API and determine their properties. With the predictive
advances in mind it is prudent, prior to physical screening for
co-crystals, to conduct a computational pre-screen. This involves the
use of computational chemistry such as utilising molecular
quantum-mechanical calculations to predict drug-co-former pairs
that are likely to form co-crystals.23 Different methods are available
from simple energy minimisation to full crystal structure predic-
tion24 and the decision on which is most appropriate will be based
on the size of the screen and the resources available. COSMOtherm
software, which performs single molecule gas phase calculations
based on polarisation charge densities, was chosen as the method
of pre-screening for this work.25 Here ROY was screened against a
list of 342 potential co-formers following a similar screening process
to that detailed by Grecu et al.26 based on the previous work by
Musumeci et al.23 This modelling led to a list of energetically
favourable combinations of co-former to ROY and those with the
greatest enthalpic driver for interaction were taken forwards to the
physical screen. The top ten from this list are shown in Table 1
ranked by excess enthalpy, obtained by subtracting the sum of
calculated enthalpy of interaction of the pure components from that
of the API-co-former mixture in the gas phase.
Physical high-throughput screening of potential co-formers with
the desired API using ultrasonication has been proven to be feasible
for this purpose with researchers employing variations such as
SonicSlurryt and sonic bath processes to introduce the sonic energy
to the samples in 96-well plates.27,28 Having adopted ultrasonication
technology for the screening process and adapted the current
methods, key parameters for co-crystal screening were optimised
to achieve a robust, cost effective process and this was applied to
ROY. This was achieved by adding a DCM/ROY solution to an
equimolar amount of solid potential co-former, which had been pre-
weighed in a borosilicate glass 96-well plate. After leaving the initial
solvent (DCM) to evaporate, acetone was added to 8 wells and the
8-tips of the ultrasonic probe were placed in these wells and
sonicated. This process was repeated for the remaining wells and
the whole process repeated a further two times replacing the solvent
used each time; thereby completing the screening process in three
solvents for 48 potential co-formers. The products from each of the
wells were analysed using FTIR (after each solvent) and compared to
the spectra for the two parent compounds.
Further details of the methods used can be found in the
ESI† (S5). Full optimisation of this screening method is
on-going and will be reported elsewhere.
Here we report the discovery of a co-amorphous form of ROY,
determined during follow up experimentation post co-crystal
screening. Based on the analysis of the FTIR spectra, the screen
applied to ROY found no evidence of the formation of co-crystals.
This was not surprising as a degree of excess enthalpy from
prediction is no guarantee of co-crystallisation in vitro, due to lack
of consideration of the purported lattice in the adopted approach.
The wavenumbers of the peaks of interest used in the analysis for
the top 10 predicted co-formers are listed in Table 1, the results in
their entirety can be found in the ESI† (S6). Further efforts to
produce co-crystals of ROY from the top 10 predicted co-formers
followed, this involved applying differentmethods ofmanufacture:
liquid assisted grinding (LAG) and evaporative crystallisation. See
ESI† for details of these methods.
The products of LAG were analysed by FTIR, the results again
listed in Table 1. In addition, the products of LAG were analysed by
DSC employing a heat/cool/heat method (see ESI† for full details).
Table 1 Top 10 predicted co-formers for ROY
Potential
co-formers
Excess
enthalpya
(DH/kJ mol1)
Wavenumber of peaks associated with bonds affected by hydrogen bonding within ROY
polymorphs
Crystallisation
in cycleb
B3300
peak
(acetone)
B2220
peak
(acetone)
B3300
peak
(ethanol)
B2220
peak
(ethanol)
B3300
peak
(hexane)
B2220
peak
(hexane)
B3300
peak
(LAG)
B2220
peak
(LAG)
Pentafluorophenol 1.953 3280 2209 +
2230
3280 2229 3003 +
3281
2210 +
2230
3281 2230 +
2240
2nd heating
Acesulfame 1.509 3280 2209 +
2230
3280 2210 +
2230
3280 2210 +
2230
3281 2230 Cooling
Oxalic acid 1.346 3282 +
3302
2209 +
2230
3279 2228 3281 2221 +
2230
3280 2229 Cooling
Quercetin 1.296 3280 2230 3279 2230 3280 2222 +
2230
3281 2230 2nd heating
Sulfamic acid 1.222 3280 2229 3280 2229 3283 2221 3280 2230 Cooling
3,5-Dinitrobenzoic
acid
1.193 3280 2210 +
2229
3280 2230 3281 2223 +
2229
3281 2230 Cooling
Pyrogallol 1.145 3278 2229 3279 2229 3280 2230 3279 2230 None
2,4-Dihydroxybenzoic
acid
1.044 3280 2229 3280 2230 3282 2222 +
2230
3279 2230 Cooling,
2nd heating
5-Nitroisophthalic
acid
1.037 3278 2229 3278 2229 3281 +
3300
2210 +
2230
3280 2230 Cooling
Gallic acid 1.032 3277 2209 +
2229
3276 2228 3278 2209 +
2230
3279 2230 Cooling
a Excess enthalpy calculated for 1 : 1, 2 : 1 and 1 : 2 stoichiometric ratios of API to co-former and ranked by lowest. b Cycle in which crystallisation
occurs during DSC of the grind of the respective co-former with ROY.
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Nine of the 10 products of LAG displayed unremarkable thermal
recrystallization behaviour, however the LAG product of ROY and
pyrogallol stood out. Pure ROY and pyrogallol show poor amor-
phous stability. Pyrogallol crystallises on cooling from melt and
ROY crystallises during the second heating cycle (class (I-A) and
class (II) materials following the classification system as described
by Baird et al.29 respectively), the product of the grind does not
crystallise and remains in amorphous form throughout the tem-
perature range tested. This suggests that an amorphous form was
produced on cooling and this remained stable until at least 150 1C
resulting in a material categorised as class (III); producing a
co-amorphous material.9 The second heating cycles for the two
parent components and the product of the 1 : 1 molar ratio grind
are shown in Fig. 2. See ESI† (S12 and S13) for the initial heating
and cooling cycles. This behaviour differs from all other ROY-co-
former combinations, as they all crystallise either on cooling (class
(I)), on the second heating phase (class (II)), or in one case both, as
shown in Table 1.
The glass transition temperatures for ROY and for the
ROY–pyrogallol 1 : 1 grind, shown in Fig. 2 and in more detail
in the ESI† (S14), vary by less than 4 1C, and as such suggest
that a change in molecular mobility great enough to affect
molecular translational ability is not caused by the presence of
pyrogallol. To determine whether the amorphous stability
elicited by the presence of the pyrogallol was related to its
stoichiometric ratio with ROY, further ROY : pyrogallol samples
were produced at 5% w/w increments from 0% to 100%,
representative thermograms of the second heating cycle are
shown in Fig. 3 and further results detailing the initial heating
cycle can be found in the ESI† (S17 and S18). The initial melting
point varies very little over the range 5% to 95% w/w pyrogallol
and therefore indicates that this is not a eutectic system, as, if it
were, a single lower melting point at the eutectic composition
would be expected.30 It is also worth noting that an endothermic
melting peak at around 88.5 1C was detected during the initial
heating cycle is present in all three samples (S17, ESI†), with
decreasing intensity as the pyrogallol content is reduced.
When looking at the second heating cycle (Fig. 3) at the 1 : 1
composition the lack of any endothermic or exothermic events
in the given temperature range suggest the 1 : 1 stabilisation
rather than a small amount of pyrogallol inhibiting the crystal-
lisation of ROY. The approximate boundaries of this range
(25% to 35% w/w pyrogallol content) equate to molar ratios
(in the form 1 ROY to X pyrogallol) of 0.69 and 1.11 respectively.
These data suggest that with a lower ratio of pyrogallol to ROY,
there is excess ROY behaving as pure ROY and uninfluenced by
the presence of pyrogallol. The formation of intermolecular
interactions between individual molecules of ROY and pyrogallol
in a one to one manner would give rise to such behaviour.
In order to explore this interaction the hydrogen bonding
propensity of ROY, with the addition of aromatic hydroxyl to
represent the potential pyrogallol interaction, was calculated using
the logit model31 resulting in an area under ROC curve of 0.86 (see
ESI,† S19–S22). This predicted strong hydrogen bonds between
molecules of ROY only. Further modelling utilising a 200 molecule
amorphous cell, generated in materials studio, displayed no change
to the N–H bond of ROY, but changes to the environment around it
(ESI,† S23–S25). IR and solution 1H NMR were conducted on a
physical sample. Solution 1H NMR showed a 1 :1 product with no
thermal degradation from themixture (ESI,† S26). Fig. 4 displays the
FTIR spectra of an amorphous sample of the ROY :pyrogallol 1 : 1
grind and a peak shift corresponding to the N–H bond in ROY is
apparent. A possible rationale, supported by the amorphous cell
prediction (ESI,† S23–S25), could be that pyrogallol forms intermo-
lecular bonds in proximity to the N–H bond of ROY causing the
slight alteration in environment of the N–H bond. Such interactions
in co-amorphous materials have previously been reported.17
In order to compare the pyrogallol-stabilised amorphous ROY
form to a more traditional polymer stabilised form, a grind of ROY
with polyvinylpyrrolidone (PVP) was created. This was at both a
typical 10% w/w drug loading, with regards to ROY, and also at a
1 : 1 molar ratio, based on the molecular weight of the PVP
monomer. Both of these ROY :PVP ratios led to stabilised amor-
phous forms being produced. These data are available in the ESI†
(S27–S30). The similarity of the ROY :pyrogallol sample to the
Fig. 2 Second heating phase DSC curves of pyrogallol (red), ROY (blue)
and ROY : pyrogallol 1 : 1 grind (green). Peak onset temperatures displayed.
Presence of Tg highlighted in inset.
Fig. 3 Second heating phase DSC curves of ROY (0%), pyrogallol (100%)
and varying compositions of ROY : pyrogallol in 5% w/w increments. The
red box highlights the range of compositions in which the amorphous
form is stabilised. This equates to 1 : 1 stoichiometry.
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behaviour seen with the ROY :PVP grind adds further evidence to
the possibility of replacing polymer with small molecule stabilising
agents in some situations.
The timescale of the stability of the ROY : pyrogallol mix was
also investigated by powder X-ray diffraction (PXRD) and DSC.
This stability was seen to be highly dependent on atmospheric
moisture conditions. Indeed samples stored under dry nitrogen
flow, or in a lidded DSC pan were seen to be stable for up to
65 hours, with those exposed to atmospheric conditions only
stable for around 30 minutes (ESI,† S33–S35). It was not
possible to verify this through vapour sorption study due to
the fast recrystallization that was seen on the instrument, but
storage at 75% RH 25 1C showed immediate visual recrystalli-
zation, which was confirmed by DSC at 18 hours (ESI,† S33). As
compared to pure ROY this is a significant improvement
however as complete recrystallization from the amorphous
form was seen after 15 minutes.
In this work the application of an optimised co-crystal
screen, utilising computational tools to predict the most ener-
getically favourable co-formers, has led to the discovery of no
co-crystals, but has highlighted a 1 : 1 interaction between ROY
and pyrogallol. This interaction stabilises ROY in the amor-
phous form, although this stability is moisture dependent.
Although predictive technology exists for single component
amorphous phases,32 currently no predictive method for co-
amorphous phases has been suggested and all screening is by
trial and error. The discovery of this behaviour stemmed from a
screen of 342 co-formers, in three stoichiometries, in which
predicted interaction had been ranked highly in the gas phase.
This suggests that co-crystal screening approaches can be
modified to enable study into co-amorphous phases and that
‘negative’ co-crystal hits should be investigated for alternative
utility as co-amorphous materials. Such an approach would
enable a broader palate of pharmaceutical development
options and improve process efficiency.
We would like to thank AstraZeneca and Durham University
for PhD funding to support the project. We would also like to
thank the Royal Society (RG130663S) for equipment.
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